Johnson & Johnson (J&J) is set to present significant findings from its solid tumor portfolio at the 2024 World Conference on Lung Cancer (WCLC) and the European Society for Medical Oncology (ESMO) 2024 Congress. Eleven oral presentations will feature new data from 27 studies across lung, bladder, prostate, and colorectal cancers, reinforcing J&J's commitment to addressing unmet needs in oncology.
Yusri Elsayed, M.D., Ph.D., Global Therapeutic Area Head, Oncology, Johnson & Johnson Innovative Medicine, stated, "Our targeted approach to treating lung, prostate, bladder, and now, colorectal cancers is on full display at this year’s WCLC and ESMO conferences."
RYBREVANT® (amivantamab-vmjw) in NSCLC and Colorectal Cancer
Key presentations will focus on RYBREVANT®, a bispecific antibody targeting EGFR and MET. The Phase 3 MARIPOSA study will present overall survival data comparing RYBREVANT® plus LAZCLUZE™ (lazertinib) to osimertinib as a first-line treatment for EGFR-mutated advanced non-small cell lung cancer (NSCLC). Initial results from the MARIPOSA study will also be presented, comparing LAZCLUZE™ monotherapy versus osimertinib in the same patient population.
Additional studies include the Phase 2 SKIPPirr study, evaluating prophylactic strategies to mitigate infusion-related reactions (IRR) with intravenous RYBREVANT®, and the Phase 3 PALOMA study, comparing subcutaneous and intravenous administration of RYBREVANT® regarding convenience and patient preference.
At ESMO, the first results from the Phase 3 MARIPOSA study will report on the impact of RYBREVANT® inhibiting EGFR and MET combined with LAZCLUZE™ and the emergence of acquired resistance versus osimertinib as first-line treatment for patients with EGFR-mutated advanced NSCLC. Longer follow-up data from the Phase 3 MARIPOSA-2 study will evaluate RYBREVANT® plus chemotherapy compared to chemotherapy alone in EGFR-mutated advanced NSCLC after disease progression on osimertinib.
Furthermore, the Phase 1b/2 OrigAMI-1 study will present initial findings on RYBREVANT® plus chemotherapy in patients with metastatic colorectal cancer, an area with significant unmet needs.
TAR-200 in Bladder Cancer
Updates from the SunRISe program will highlight TAR-200, an investigational targeted releasing system for bladder cancer. Late-breaking interim analysis results from the Phase 2 SunRISe-4 study will evaluate neoadjuvant TAR-200 plus cetrelimab or cetrelimab alone in patients with muscle-invasive bladder cancer ineligible for platinum-based chemotherapy. Longer follow-up data from the pivotal Phase 2b SunRISe-1 study will report on TAR-200 alone and in combination with cetrelimab in Bacillus Calmette-Guérin-unresponsive, high-risk non–muscle-invasive bladder cancer.
JNJ-87189401 and JNJ-78278343 in Prostate Cancer
The first presentation of a trial in progress from the first-in-human Phase 1 study evaluating JNJ-87189401, a prostate-specific membrane antigen (PSMA)-CD28 bispecific antibody, in combination with JNJ-78278343, a kallikrein 2 (KLK2)-CD3 bispecific antibody, in patients with advanced prostate cancer will also be presented.
